Total Payments
$432,287
2024 Payments
$68,971
Companies
44
Transactions
1,134
Medicare Patients
4,657
Medicare Billing
$977,171
Payment Breakdown by Category
Other$369,981 (85.6%)
Travel$32,649 (7.6%)
Food & Beverage$19,657 (4.5%)
Consulting$9,724 (2.2%)
Education$275.14 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $345,756 | 209 | 80.0% |
| Travel and Lodging | $32,649 | 166 | 7.6% |
| Honoraria | $24,225 | 11 | 5.6% |
| Food and Beverage | $19,657 | 726 | 4.5% |
| Consulting Fee | $9,724 | 9 | 2.2% |
| Education | $275.14 | 13 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $129,929 | 227 | $0 (2024) |
| Relypsa, Inc. | $101,191 | 193 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $98,878 | 129 | $0 (2024) |
| Vifor Pharma, Inc. | $37,622 | 65 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $25,584 | 33 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $17,955 | 33 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $10,235 | 56 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,315 | 2 | $0 (2021) |
| Amgen Inc. | $1,252 | 59 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $1,200 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68,971 | 173 | CALLIDITAS THERAPEUTICS US INC. ($25,495) |
| 2023 | $56,428 | 136 | AstraZeneca Pharmaceuticals LP ($37,619) |
| 2022 | $109,313 | 189 | Bayer HealthCare Pharmaceuticals Inc. ($45,118) |
| 2021 | $81,854 | 163 | AstraZeneca Pharmaceuticals LP ($39,305) |
| 2020 | $25,365 | 93 | Relypsa, Inc. ($24,285) |
| 2019 | $48,052 | 155 | Relypsa, Inc. ($46,650) |
| 2018 | $35,951 | 132 | Relypsa, Inc. ($30,070) |
| 2017 | $6,354 | 93 | Otsuka America Pharmaceutical, Inc. ($5,127) |
All Payment Transactions
1,134 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $1,900.00 | General |
| Category: Nephrology | ||||||
| 12/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Nephrology | ||||||
| 12/11/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $15.33 | General |
| 12/10/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $950.00 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Cardio-renal | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Nephrology | ||||||
| 11/26/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/20/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $120.60 | General |
| Category: Nephrology | ||||||
| 11/20/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $14.74 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: NEPHROLOGY | ||||||
| 11/13/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Nephrology | ||||||
| 11/12/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Inflammation | ||||||
| 11/07/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,850.00 | General |
| Category: Nephrology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/06/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $242.54 | General |
| Category: Nephrology | ||||||
| 11/05/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Nephrology | ||||||
| 10/31/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Nephrology | ||||||
| 10/29/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: Nephrology | ||||||
| 10/29/2024 | Amgen Inc. | Aranesp (Biological) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Nephrology | ||||||
| 10/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Cardio-renal | ||||||
| 10/17/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: NEPHROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,163 | 2,350 | $600,513 | $226,625 |
| 2022 | 17 | 1,127 | 2,527 | $656,991 | $237,384 |
| 2021 | 17 | 1,142 | 2,615 | $662,130 | $264,076 |
| 2020 | 21 | 1,225 | 2,647 | $568,041 | $249,086 |
Total Patients
4,657
Total Services
10,139
Medicare Billing
$977,171
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 47 | 258 | $177,246 | $68,765 | 38.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 355 | 451 | $110,495 | $37,705 | 34.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 119 | 366 | $71,736 | $32,977 | 46.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 117 | 368 | $50,048 | $21,457 | 42.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 35 | 72 | $40,896 | $16,216 | 39.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 77 | 87 | $33,060 | $11,154 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 86 | 86 | $27,262 | $8,076 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 59 | $20,237 | $7,115 | 35.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 49 | 61 | $15,738 | $5,848 | 37.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 22 | 149 | $16,688 | $5,131 | 30.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 24 | 113 | $10,735 | $4,015 | 37.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 21 | $11,088 | $3,403 | 30.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 145 | 230 | $7,590 | $1,856 | 24.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,598 | $1,819 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 18 | $3,096 | $1,086 | 35.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 48 | 294 | $199,254 | $78,166 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 337 | 435 | $106,575 | $30,488 | 28.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 131 | 489 | $66,504 | $26,203 | 39.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 90 | 264 | $51,744 | $20,143 | 38.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 38 | 92 | $52,256 | $20,066 | 38.4% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 11 | 48 | $27,264 | $10,698 | 39.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 65 | 99 | $25,542 | $9,804 | 38.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 63 | 67 | $25,460 | $9,431 | 37.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 81 | 81 | $25,677 | $9,282 | 36.1% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 31 | 245 | $27,440 | $9,069 | 33.1% |
About Dr. Ross Nesbit, MD
Dr. Ross Nesbit, MD is a Internal Medicine healthcare provider based in Knoxville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2009. The National Provider Identifier (NPI) number assigned to this provider is 1386870475.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ross Nesbit, MD has received a total of $432,287 in payments from pharmaceutical and medical device companies, with $68,971 received in 2024. These payments were reported across 1,134 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($345,756).
As a Medicare-enrolled provider, Nesbit has provided services to 4,657 Medicare beneficiaries, totaling 10,139 services with total Medicare billing of $977,171. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Knoxville, TN
- Active Since 06/03/2009
- Last Updated 03/07/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1386870475
Products in Payments
- Veltassa (Drug) $136,064
- FARXIGA (Drug) $129,389
- Kerendia (Drug) $98,878
- TARPEYO (Drug) $25,584
- LUPKYNIS (Drug) $17,955
- SAMSCA (Drug) $9,883
- INVOKANA (Drug) $1,315
- FUROSCIX (Drug) $1,200
- ACTHAR (Biological) $1,197
- ZEMDRI (PLAZOMICIN) (Drug) $1,000
- KRYSTEXXA (Biological) $586.49
- LOKELMA (Drug) $474.01
- Parsabiv (Drug) $383.93
- Velphoro (Drug) $364.15
- Parsabiv (Biological) $359.89
- JYNARQUE (Drug) $352.08
- INJECTAFER (Drug) $308.25
- Rayaldee (Drug) $278.43
- ULTOMIRIS (Biological) $251.50
- AURYXIA (Drug) $246.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Knoxville
Dr. Dennis Deruelle, Md, Fhm, MD, FHM
Internal Medicine — Payments: $289,726
Internal Medicine $289,726
Ayaz Rahman, M.d, M.D
Internal Medicine — Payments: $250,855
Internal Medicine $250,855
Dr. David Chism, Md, MD
Internal Medicine — Payments: $47,436
Internal Medicine $47,436
Morgan Randall
Internal Medicine — Payments: $45,633
Internal Medicine $45,633
Kimberly Morris, Md, MD
Internal Medicine — Payments: $32,540
Internal Medicine $32,540
Michael Hill, Md, MD
Internal Medicine — Payments: $27,169
Internal Medicine $27,169